- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Snapshot for XOMA Corp (XOMA)
| Open: | 2.3500 | Day's Range: | 2.3401 - 2.5300 | Volume: | 804,238 | Bid: | 2.4800 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 2.3800 | 52wk Range: | 1.0400 - 3.1400 | 1-Yr Rtn: | -17.49% | Ask: | 2.5000 |
Key Statistics for XOMA
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -1.0300 |
| Est. EPS (USD) (12/2012) | -1.1700 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 170.21 |
| Shares Outstanding (M) | 68.08 |
| Enterprise Value (M USD) (ttm) | 131.69 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 8.7331 |
| Price/Sale (ttm) | 1.6059 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/03/2012 |
More XOMA Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for XOMA
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for XOMA
XOMA Corporation is a biopharmaceutical company that develops and manufactures genetically engineered protein, peptide, and antibody pharmaceuticals. The Company's medical targets include bacterial and fungal infections, infectious complications, and immunologic and inflammatory disorders. XOMA's primary drug development platform is bactericidal/permeability-increasing protein.
| W Denman Van NessChairman | John VarianChief Executive Officer |
| Patrick J ScannonExec VP/Chief Scientific Ofcr | Fred KurlandVP:Finance/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page